Condition: Intracerebral Hemorrhage · Atrial Fibrillation · Microhaemorrhage · Sponsor: University Hospital, Lille
Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF). However, these RCTs excluded patients with prior intracerebral haemorrhage (ICH). Therefore, guidelines are unable to recommend whether oral anticoagulant drugs, in particular non-vitamin K antagonist (called direct OAC) - can be used for patients with AF after an intracerebral haemorrhage. Roughly 30% of adults with ICH have AF but in 2017 it remains unclear whether they should start oral anticoagulant drugs, be treated with left atrial appendage closure (LAAC) or avoid anticoagulation and LAAC.
This description comes directly from the study's public registry record.
Charlotte Cordonnier, MD, PhD · 3 20 44 68 14 · charlotte.cordonnier@chru-lille.fr
Always discuss trial participation with your own doctor first.
| Hôpital Roger Salengro, CHU | Lille, France | Recruiting |
| GHICL | Lomme, France | Recruiting |
| CH De Tourcoing | Tourcoing, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03243175